Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Expert Review of Anticancer Therapy|August 30, 2017
Second-line treatments of small-cell lung cancersNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.Epidemiology (Cambridge, Mass.)|October 12, 2004
Indoor radon and lung cancer in FranceHélène Baysson, Margot Tirmarche, Georges Tymen, et al.Expert Review of Anticancer Therapy|September 4, 2018
Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic reviewPaul Lesueur, Isabelle Martel-Laffay, Alexandre Escande, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 15, 2010
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 studyAlain Vergnenegre, Romain Corre, Henri Berard, et al.Clinical Lung Cancer|June 12, 2012
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)Christos Chouaid, Hervé Le Caer, Romain Corre, et al.Pulmonary Pharmacology & Therapeutics|May 18, 2010
Biomarkers in lung oncologyRafael Rosell, Alain Vergnenegre, Baorui Liu, et al.Future Oncology (London, England)|February 13, 2015
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trialFilippo de Marinis, Alain Vergnenegre, Antonio Passaro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.Journal of the American Academy of Dermatology|March 8, 2016
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trialGaël Deplanque, Radj Gervais, Alain Vergnenegre, et al.International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax RiskThomas Egenod, Jeremy Tricard, Romane Fumat, et al.Pageof 6